Anticoagulants in cancer

An Overview of Novel Anticoagulants

Arterial and venous thromboembolism is one of the most common causes of death worldwide. For almost seventy years, heparin, low molecular weight heparin, and vitamin K antagonists have been widely used in the prevention and treatment of thromboembolic disorders. However, many of the limitations of these traditional anticoagulants have led to the search for and attempts to introduce better drug ...

[Anticoagulants].

Anticoagulants are effective in the prevention and treatment of a variety of arterial and venous thrombotic disorders but are associated with an increased risk of serious bleeding complications. Based on well documented studies of patients using vitamin K antagonists the incidence of major bleeding is 0.5%/year and the incidence of intracranial bleeding is 0.2%/year, however, in real life pract...

Anticoagulants in pregnancy.

Lupus anticoagulants in children.

Although a great deal of information is available in the literature on the frequency, clinical/laboratory findings and significance of lupus anticoagulants in adults, little is known about such acquired inhibitors in children. Clinical and laboratory findings are presented on seven non-hemophiliac children, four females and three males, ranging in ages from three to 14 years, who developed such...

New anticoagulants in children.

Thromboembolic complications are increasing in children and the use of anticoagulation has seen a dramatic increase despite the lack of randomized clinical trials. The most widely used agents in children are heparin, low-molecular-weight heparins (LMWH), and warfarin. These agents, however, have significant limitations that are exaggerated in children. Novel anticoagulants such as direct thromb...